Home > Boards > US OTC > Biotechs > Ampio Pharmaceuticals, Inc (AMPE)

AMPIO PHARMACEUTICALS INVESTMENT HIGHLIGHTS

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
conix Member Profile
 
Followed By 166
Posts 26,022
Boards Moderated 10
Alias Born 10/10/05
160x600 placeholder
Quarterly Report (10-q) Edgar (US Regulatory) - 11/7/2019 4:34:23 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 10/31/2019 4:31:35 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/29/2019 6:03:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/21/2019 4:36:09 PM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 10/16/2019 4:03:18 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/10/2019 4:02:31 PM
Ampio Provides Update on Continued Progress of AP-013 Phase III Clinical Trial and Manufacturing Facility PR Newswire (US) - 10/10/2019 8:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/20/2019 4:02:57 PM
Ampio Retains Legal Counsel for Transaction Advisory Committee PR Newswire (US) - 9/18/2019 8:30:00 AM
Ampio Pharmaceuticals Updates Progress of SPA Clinical Trial PR Newswire (US) - 9/17/2019 8:30:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/11/2019 5:47:09 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/11/2019 5:32:22 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/11/2019 5:13:54 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/23/2019 4:03:17 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/22/2019 3:05:35 PM
Ampio Pharmaceuticals Retains Financial Advisor and Appoints Transaction Advisory Committee PR Newswire (US) - 8/22/2019 8:30:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/9/2019 4:04:18 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/1/2019 5:23:37 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 8/1/2019 5:01:31 PM
Ampio Pharmaceuticals Updates Progress of SPA Clinical Trial PR Newswire (US) - 7/25/2019 8:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/11/2019 4:02:23 PM
Ampio Appoints Moss Adams LLP as the Company's New Independent Auditor PR Newswire (US) - 7/11/2019 8:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/10/2019 4:03:12 PM
Ampio Appoints Dan Stokely as the Company's new Chief Financial Officer PR Newswire (US) - 7/10/2019 8:30:00 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 6/20/2019 3:47:52 PM
conix   Tuesday, 08/27/19 01:38:25 PM
Re: Maintenance_Man post# 729
Post # of 739 
AMPIO PHARMACEUTICALS INVESTMENT HIGHLIGHTS

*Osteoarthritis is an incurable, progressive, chronic, degenerative and inflammatory disease.

*CDC estimates that it affects over 30 million adults in the U.S./ Hundreds of Millions Worldwide

*Degenerative Arthritis is the most common cause of knee pain - probability is over 50% getting it.

*Standard of Care is: steroid injection; total knee replacement; other opiods

*Company's drug candidate - "Ampion" - seeks to address this in severe knee pain(OAK)

*Has agreement with FDA on a SPA on the design of pivotal Phase III trial

*Company has in-house manufacturing capabilities for 'Ampion'

*Trial seeks 1000 patients with primary endpoint of pain and function

Currently, over 280 have enrolled in the study and over half have received Ampion

*Trial readout in 2020.

*'Ampion' Method of Action has potential for other inflammatory indications/conditions in human body

Ticker: AMPE

H-L:$0.36 - $1.31

Market Cap:$ 65 Million

About Ampio Pharmaceuticals:

Ampio Pharmaceuticals is a development stage biopharmaceutical company focused on the discovery and development of novel therapies aimed at treating common inflammatory conditions for which there are limited treatment options. We are developing compounds that serve significant medical needs in osteoarthritis, diabetic macular edema, and other prevalent, inflammatory diseases through an innovative discovery and development platform.

www.ampiopharma.com

Successful Trading is the art of minimizing long term risk and maximizing capital allocation.
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist